Lysosomal dysfunction and neurodegeneration Lysosomal dysfunction is a prominent pathological hallmark of NDDs
Only 4.1% of the 4 mg group stopped treatment because of adverse events, compared with 6.9% at 9 mg, 11.3% at 12 mg and 4.9% with placebo
Strength training supports mental health too Many people start GLP-1 medication to address physical health concerns, but they often stick with their new habits because of how it makes them feel not just physically, but mentally
o outro carrega efeitos colaterais que o tornam clinicamente inferior para a maioria das indicaes
REM) for triglycerides (Figs S3ac)
Such limitations make it difficult to distinguish true sensory modulation from conditioned aversion secondary to nausea or early satiety effects that are well documented across GLP-1RA trials (153, 157, 173, 180)